Pieris Pharmaceuticals Inc expected to post a loss of 30  cents a share - Earnings Preview

Palvella Therapeutics

25/02/2022 14:40

* Pieris Pharmaceuticals Inc  PIRS.OQ   PIRS.O  is expected
to show a rise in quarterly revenue when it reports  results on
March 1. 
    * The Boston Massachusetts-based  company is expected to
report  a
30.7% increase in revenue to $2.454 million from $1.88 million a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Pieris
Pharmaceuticals
Inc is for a loss of 30 cents per share. For the same quarter
last year, the company reported a loss of 26 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Pieris
Pharmaceuticals Inc is $8​, about 61.7% above​ its last closing
price of $3.06. ​​​

This summary was machine generated February 25 at 14:40 GMT. 
All figures in US dollars  unless otherwise stated